Testanon250 mg/ml

Testanon is a long-acting testosterone ester used as part of injectable androgen replacement therapy. It is typically formulated together with other testosterone esters (propionate, phenylpropionate, isocaproate) in a single intramuscular injection to provide both rapid and sustained release of testosterone.

Established/Approved Uses

• Male hypogonadism: Testosterone replacement therapy in adult males with primary hypogonadism (congenital or acquired testicular failure, e.g. cryptorchidism, orchitis, orchidectomy, Klinefelter syndrome) or hypogonadotropic hypogonadism (idiopathic gonadotropin/LH-RH deficiency, or pituitary-hypothalamic injury from tumours, trauma, or radiation), when the diagnosis has been confirmed by clinical features and biochemical (laboratory) testing.

Guideline-Supported / Adjunct Uses

• Gender-affirming hormone therapy (masculinization) in female-to-male transgender individuals, under specialist endocrinology supervision.
• Delayed puberty in adolescent males due to confirmed hypogonadism, under paediatric endocrinology supervision (short courses only).

Not Recommended / Off-Label Caution

• Testanon is not indicated for age-related decline in testosterone ("low T") without confirmed pathological hypogonadism, and is not approved for enhancement of athletic performance or physique, which carries serious cardiovascular and psychiatric risks (see Precautions and Warnings).

Testanon is a long-acting ester of the natural male sex hormone testosterone. Esterification with decanoic acid slows absorption from the intramuscular injection site, allowing the hormone to be released gradually into the bloodstream over an extended period, which reduces the frequency of injections needed compared with unesterified testosterone.

Once absorbed, Testanon is hydrolyzed by plasma esterases to release free testosterone, which then exerts the same physiological effects as endogenous testosterone. It is generally administered as part of a combined-ester injectable product to combine an early (faster-acting ester) and later (slower-acting decanoate) release profile within a single dosing interval.

Testanon belongs to the androgen / anabolic steroid therapeutic class. It is classified as a long-acting injectable testosterone ester used for androgen replacement therapy.

Testosterone Decanoate is hydrolyzed after intramuscular absorption to release testosterone, the principal endogenous androgen. Testosterone binds to androgen receptors in target tissues (genital tissue, muscle, bone, hair follicles, CNS, and others) to regulate the development and maintenance of male primary and secondary sexual characteristics, spermatogenesis, libido, and anabolic (protein-building) processes such as muscle and bone mass.

Pharmacodynamics

• Increases plasma testosterone, dihydrotestosterone (DHT), and oestradiol concentrations.
• Decreases sex hormone-binding globulin (SHBG).
• Stimulates erythropoiesis (red blood cell production), which can raise haemoglobin/haematocrit.
• Promotes nitrogen retention and protein anabolism (muscle and bone).
• Suppresses hypothalamic-pituitary gonadotropin (LH/FSH) secretion via negative feedback, which can reduce endogenous testosterone production and spermatogenesis.

Pharmacokinetics

• After intramuscular injection, Testosterone Decanoate (the slower-releasing ester in a mixed-ester product) contributes to sustained plasma testosterone levels, with peak concentrations generally seen within 24-48 hours after injection and a gradual decline back toward baseline over roughly 3 weeks, depending on the specific ester blend and dose.
• Testosterone is metabolized primarily in the liver to inactive metabolites (also partly to active metabolites DHT and oestradiol) and excreted mainly in urine as glucuronide/sulfate conjugates, with a smaller portion in faeces.

Testanon has the following well-documented, clinically significant interactions:

• Oral anticoagulants (e.g. warfarin): Testanon may enhance anticoagulant effect, increasing bleeding risk; more frequent INR monitoring and dose adjustment of the anticoagulant may be required.
• Insulin and oral hypoglycaemic agents: Testanon can improve glucose tolerance and may reduce insulin/antidiabetic drug requirements; blood glucose should be monitored, especially at initiation or dose change.
• ACTH or corticosteroids: Concurrent use with Testanon may increase the risk of oedema (fluid retention); caution is advised, particularly in patients with cardiac, hepatic, or renal disease.
• CYP3A4 enzyme inducers/inhibitors: Drugs that induce hepatic enzymes may reduce testosterone levels, while enzyme inhibitors may increase them; clinical response and testosterone levels should guide dose adjustment.

Side effects of Testanon are generally dose-related and reflect excess androgenic activity.

Common

• Acne, oily skin
• Injection-site pain, induration, or reaction
• Increased haematocrit/haemoglobin (polycythaemia)
• Weight gain, fluid and sodium retention (oedema)
• Increased libido; in some cases, increased frequency of erections
• Gynaecomastia (breast enlargement/tenderness), due to peripheral conversion to oestrogen

Less Common / Serious

• Hepatic dysfunction (abnormal liver enzymes, rarely jaundice)
• Priapism (prolonged, painful erection) - requires urgent medical attention
• Oligospermia/azoospermia and reduced testicular size with prolonged use, due to suppression of endogenous gonadotropins
• Worsening of sleep apnoea
• Mood changes, aggression, or psychiatric disturbance
• Rare pulmonary oil microembolism reaction (cough, dyspnoea, dizziness) immediately after injection of oily testosterone formulations
• In women (if inadvertently exposed or used off-label): virilization - deepening of voice, hirsutism, clitoromegaly, menstrual irregularities (partly irreversible)
• Prepubertal boys: precocious sexual development, phallic enlargement, premature epiphyseal closure with resultant compromised final adult height

Testanon is contraindicated in pregnancy. Androgens can cause virilization of a female fetus (e.g. clitoral enlargement, abnormal vaginal development, voice changes), and Testanon is not indicated for use in women. If pregnancy occurs or is suspected during inadvertent exposure, discontinue immediately and consult a physician.

Testanon is not recommended during breastfeeding, as it is not indicated for use in women and there is insufficient data on excretion into breast milk; if use cannot be avoided in an exceptional clinical circumstance, a physician should weigh potential risks to the infant against benefit and monitor closely.

Boxed Warning (Class Warning for Testosterone Products)

Testanon and other testosterone products carry a risk of misuse and abuse for non-approved purposes such as physique or athletic enhancement, which has been associated with serious cardiovascular events (heart attack, stroke) and psychiatric adverse effects (aggression, mania, dependence). Testanon should be prescribed and used only for confirmed medical indications under physician supervision, and is a controlled substance in many jurisdictions due to this abuse potential.

Cardiovascular Risk

Testanon can increase haematocrit/haemoglobin (polycythaemia), which may raise the risk of thromboembolic events (deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction). Periodic haematocrit monitoring is recommended, and treatment should be interrupted or discontinued if haematocrit rises excessively.

Prostate Monitoring

Testanon may accelerate growth of subclinical prostate cancer or cause benign prostatic hyperplasia to worsen. PSA testing and digital rectal examination are recommended before starting and periodically during therapy in appropriate age groups.

Hepatic Effects

Injectable esters such as Testanon carry a lower hepatotoxicity risk than 17-alpha-alkylated oral androgens, but liver function should still be monitored periodically, particularly with long-term use.

Sleep Apnoea

Testanon may worsen obstructive sleep apnoea; use with caution in patients with this condition or associated risk factors (obesity, chronic lung disease).

Fluid Retention

Use with caution in patients with cardiac failure, hypertension, renal impairment, or epilepsy, as Testanon can cause sodium and fluid retention that may worsen these conditions.

Peanut/Soya Allergy

Some formulations of Testanon use arachis (peanut) oil as a vehicle; patients with known peanut or soya allergy should avoid these formulations.

Acute overdose with Testanon is unlikely to cause life-threatening toxicity given its slow-release depot formulation, but excessive or prolonged supra-therapeutic dosing can lead to pronounced androgenic and anabolic effects, including polycythaemia, priapism, severe fluid retention, hypertension, and psychiatric disturbance. If overdose is suspected, seek immediate medical attention or contact a poison control centre/emergency services. Management is supportive - discontinuing Testanon and treating specific symptoms (e.g. therapeutic phlebotomy for severe polycythaemia) under medical supervision.

Store at room temperature (below 30°C), protected from light and moisture. Do not freeze or refrigerate the oily injection unless the product label specifically states otherwise. Keep out of reach of children.

Pediatric Use

Testanon is not routinely recommended in children. In prepubertal boys, it may occasionally be used short-term under paediatric endocrinology supervision for confirmed hypogonadism or constitutional delay of puberty, but carries risk of precocious sexual development and premature epiphyseal closure with compromised final height; safety and efficacy for general paediatric use have not been established. Formulations containing benzyl alcohol should be avoided in neonates and young infants.

Use in the Elderly

Older men receiving Testanon may be at increased risk of prostate enlargement/cancer and cardiovascular events; use only with confirmed hypogonadism (not for age-related testosterone decline alone), and monitor PSA, haematocrit, and cardiovascular status closely.

Hepatic/Renal Impairment

Testanon should be used cautiously with close monitoring in mild-to-moderate hepatic or renal impairment, and is contraindicated in severe impairment of either organ.

Women

Testanon is not indicated for use in women outside specialist gender-affirming hormone therapy, due to virilization risk.

Androgen; Anabolic-androgenic steroid; Testosterone ester (long-acting)

Testanon is not approved for general paediatric use. It may be used cautiously and only under paediatric endocrinology supervision for confirmed hypogonadism or significantly delayed puberty in adolescent boys, using the lowest effective dose for the shortest necessary duration to minimize risks of precocious sexual development, phallic enlargement, and premature closure of bone growth plates (epiphyses), which can permanently reduce adult height. Safety and efficacy of Testanon in children under 3 years of age have not been established, and formulations containing benzyl alcohol should be avoided in this age group.